IDH2 and astrocytoma (excluding glioblastoma): No significant differences were noted in terms of frequency of additional chemotherapies (P = .0909) or radiotherapy (P = .7307) in IDH-mutant astrocytomas with or without MMR mutation gain or frequency of additional chemotherapies (P = .0828) or radiotherapy (P = .9689) in IDH-wild-type glioblastomas.